Phase 3 NEPTUNE Study will begin Prescreening August 1

The NEPTUNE study will evaluate the safety and effectiveness of an investigational medicine called OV101 on various aspects associated with Angelman syndrome in individuals age 2 – 12 years old.

The online pre-screening process will open on August 1, 2019 for ages 9 – 12.  The second age group (beginning November/December) will be ages 4-8. The third age group (beginning January/February 2020) will be ages 2-3.